Skudexa 75+25 mg granulat til oral opløsning i brev Danemark - danois - Lægemiddelstyrelsen (Danish Medicines Agency)

skudexa 75+25 mg granulat til oral opløsning i brev

menarini international operation - dexketoprofentrometamol, tramadolhydrochlorid - granulat til oral opløsning i brev - 75+25 mg

Enantyum 12,5 mg filmovertrukne tabletter Danemark - danois - Lægemiddelstyrelsen (Danish Medicines Agency)

enantyum 12,5 mg filmovertrukne tabletter

laboratorios menarini s.a. - dexketoprofentrometamol - filmovertrukne tabletter - 12,5 mg

Hypoloc Comp 5+25 mg filmovertrukne tabletter Danemark - danois - Lægemiddelstyrelsen (Danish Medicines Agency)

hypoloc comp 5+25 mg filmovertrukne tabletter

menarini international operation luxembourg s.a. - hydrochlorthiazid, nebivololhydrochlorid - filmovertrukne tabletter - 5+25 mg

Revitelle 2,5 mg/ml oral opløsning Danemark - danois - Lægemiddelstyrelsen (Danish Medicines Agency)

revitelle 2,5 mg/ml oral opløsning

menarini international operation luxembourg s.a. - bilastin - oral opløsning - 2,5 mg/ml

Revitelle 10 mg smeltetabletter Danemark - danois - Lægemiddelstyrelsen (Danish Medicines Agency)

revitelle 10 mg smeltetabletter

menarini international operation luxembourg s.a. - bilastin - smeltetabletter - 10 mg

Nexpovio Union européenne - danois - EMA (European Medicines Agency)

nexpovio

stemline therapeutics b.v. - selinexor - multipelt myelom - antineoplastiske midler - nexpovio is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Orserdu Union européenne - danois - EMA (European Medicines Agency)

orserdu

stemline therapeutics b.v. - elacestrant - bryst neoplasmer - endokrine terapi - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.

Bretaris Genuair Union européenne - danois - EMA (European Medicines Agency)

bretaris genuair

covis pharma europe b.v. - aclidinium bromide - pulmonal sygdom, kronisk obstruktiv - medicin for obstruktiv sygdomme, - bretaris genuair er indiceret som vedligeholdelsesbronkodilatorbehandling for at lindre symptomer hos voksne patienter med kronisk obstruktiv lungesygdom (copd).

Brimica Genuair Union européenne - danois - EMA (European Medicines Agency)

brimica genuair

covis pharma europe b.v. - formoterol fumarate dihydrate, aclidinium bromide - pulmonal sygdom, kronisk obstruktiv - medicin for obstruktiv sygdomme, - brimica genuair er indiceret som vedligeholdelsesbronkodilatorbehandling for luftstrømningsobstruktion og lindring af symptomer hos voksne patienter med kronisk obstruktiv lungesygdom (copd).

Laventair Ellipta (previously Laventair) Union européenne - danois - EMA (European Medicines Agency)

laventair ellipta (previously laventair)

glaxosmithkline (ireland) limited - umeclidinium bromid, vilanterol - pulmonal sygdom, kronisk obstruktiv - medicin for obstruktiv sygdomme, - laventair ellipta er anført som vedligeholdelse bronkodilaterende behandling til at lindre symptomer i voksne patienter med kronisk obstruktiv lungesygdom (kol).